|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 985-993, March 2003
Cardiac Medicine, National Heart and Lung Institute, Imperial College London, United Kingdom (R.L., P.C., K.T.M.); and Wake Forest University School of Medicine, Winston-Salem, North Carolina (J.K.W.)
| |
Abstract |
|---|
|
|
|---|
Soy-derived isoflavones appear to possess cardioprotective properties, although the precise nature of this protection and the particular isoflavones responsible remain unclear. We hypothesized that isoflavones may differ in their cardiac actions in view of their varying affinities for the estrogen receptor and differences in ability to inhibit tyrosine kinase. We investigated the direct effects of three closely related isoflavones, genistein, daidzein, and equol (a metabolite of daidzein formed by gut microflora), on the contractile function of isolated guinea pig ventricular myocytes. Genistein (10 and 40 µM) significantly increased cell shortening and the Ca2+ transient (measured using indo-1). In contrast, equivalent concentrations of equol produced the opposite effect, decreasing cell shortening and the Ca2+ transient, whereas daidzein was without effect. The opposing actions of genistein and equol were still observed in the presence of the specific estrogen receptor antagonist ICI 182,780 (10 µM). However, the stimulatory actions of genistein were markedly reduced in the presence of the potent phosphotyrosine phosphatase inhibitor, bpV(phen). Both genistein and equol significantly inhibited the peak L-type Ca2+ current. We conclude that genistein and equol affect the contractile function of ventricular myocytes in opposing ways despite a common initial action of Ca2+ current antagonism. These differences occur independently of the estrogen receptor but may be partly related to the unique actions of genistein as a tyrosine kinase inhibitor. Furthermore, isoflavone metabolites, such as equol, may be more biologically active than their precursors and have a greater role in cardioprotection than previously realized.
| |
Introduction |
|---|
|
|
|---|
Epidemiological
evidence suggests that dietary isoflavones, which are major
constituents of soy products, may possess cardioprotective properties
(Adlercreutz, 1990
; Adlercreutz et al., 1993
; Artaud-Wild et al.,
1993
). This may in part be due to favorable effects on the lipid
profile, as isoflavones increase high-density lipoprotein and
lower low-density lipoprotein cholesterol levels (Cassidy et al., 1995
;
Anthony et al., 1998
). However, isoflavones have also been shown to
produce direct actions on the cardiovascular system, which may
contribute toward cardioprotection (Figtree et al., 2000
; Chin-Dusting
et al., 2001
).
The two main isoflavones found in soy products are genistein and
daidzein (Tham et al., 1998
), both of which undergo further metabolism
by gut microflora to produce additional compounds (Chang and Nair,
1995
; Chang et al., 1995
). Equol, the isoflavone metabolite produced
from the hydrogenation of daidzein, is of particular interest, as in
vitro experiments suggest that it may be more potent than other
isoflavones, including the parent compound (Chang et al., 1995
;
Sathyamoorthy and Wang, 1997
; Morito et al., 2001
). All three
isoflavones are known to interact with both estrogen receptor (ER)
and
, although they have a greater affinity for the latter (Kuiper
et al., 1998
). Moreover, they differ with respect to their binding
affinities for the ERs. For example, both genistein and equol have a
greater affinity for the ER than daidzein (Sathyamoorthy and Wang,
1997
; Kuiper et al., 1998
). In addition, genistein differs from the
other two isoflavones in its ability to inhibit tyrosine kinase (TK)
(Akiyama et al., 1987
; Schultze-Mosgau et al., 1998
). Therefore,
important differences exist between these three isoflavones despite
close structural similarities (Tham et al., 1998
).
All three isoflavones directly relax arterial ring preparations in
vitro (Figtree et al., 2000
; Chin-Dusting et al., 2001
), and genistein
and daidzein have been reported to inhibit the L-type Ca2+ current,
ICa,L, in isolated cardiac myocytes
(Yokoshiki et al., 1996
; Ogura et al., 1999
). It has been assumed that
this results in an overall inhibition of cell contraction, although
this has not been well explored. Major unresolved issues include
whether the cardioprotective effects of isoflavones are largely
attributable to a group effect or to a particular isoflavone and
whether the cardiovascular actions of isoflavones are all beneficial.
These questions are particularly relevant in view of the increasing availability of isoflavone supplements, many of which contain genistein
and daidzein (Djuric et al., 2001
; Lewis et al., 2002
).
The aim of the present study was to investigate the hypothesis that soy-derived isoflavones exert different actions on isolated cardiac myocytes. We studied the direct effects of genistein, daidzein, and equol on cell contraction and further investigated whether any observed differences could be attributed to their varying affinities for the ER or the unique properties of genistein as a TK inhibitor. We report here the novel finding that genistein and equol produce directly opposing cardiac actions and discuss the possible mechanisms involved.
| |
Materials and Methods |
|---|
|
|
|---|
Cardiomyocyte Isolation.
Left ventricular myocytes were
isolated from adult male guinea pigs (weighing 350-550 g) using a
Langendorff apparatus and enzymatic digestion as previously described
(MacLeod and Harding, 1991
). All procedures conformed to the
Guide for the Care and Use of Laboratory Animals published
by the National Institutes of Health. Myocytes were stored in
Dulbecco's modified Eagle's medium solution at room temperature and
used within 6 to 8 h of isolation.
Cell Loading. Cells were incubated at room temperature with 10 µM of the acetoxymethyl ester form of the Ca2+-sensitive fluorescent dye, indo-1 (Molecular Probes, Eugene, OR). After 25 min, the supernatant was removed and replaced with fresh Dulbecco's modified Eagle's medium. Cells were not used for at least another 30 min to allow the intracellular indo-1 to be de-esterified.
Effect of Isoflavones on in Vivo Calibration of Indo-1.
To
use indo-1 to measure the Ca2+ transient, we
first established whether the isoflavones studied affected the indo-1
signal other than via changes in intracellular
Ca2+. Calibration experiments were performed to
determine the in vitro indo-1 dissociation constant
(Kd) and in vivo minimum and maximum fluorescence ratios (Rmin and
Rmax) (Bassani et al., 1993
; Kao, 1994
) in the presence and absence of 40 µM of each isoflavone. Genistein (Sigma Chemical, Poole, Dorset, UK) and equol
(Indofine Chemical Company, Inc., Somerville, NJ) did not significantly affect the above parameters (n = 5). However, daidzein
(Sigma Chemical) significantly decreased the in vitro
Kd and in vivo Rmin of indo-1 as well as
unpredictably decreasing the Rmax in some cells, although this was not significant (n = 5).
Therefore, we were unable to reliably measure the
Ca2+ transient using indo-1 in the presence of
daidzein. As each cell acted as its own control, the indo-1 ratios
measured in the presence of genistein and equol could be expressed as a
percentage of that measured in control solution, without the need to
calculate the absolute intracellular Ca2+ concentration.
Cell Shortening and Intracellular Ca2+
Measurements.
Cells were placed on the coverslip base of a
superfusion chamber mounted on the stage of an inverted microscope.
They were superfused with normal Tyrode's (NT) solution (containing
140 mM NaCl, 6 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 10 mM glucose, and 10 mM HEPES, pH
adjusted to 7.4 using NaOH) delivered at a rate of 2 ml/min. Cells were
field stimulated at 1 Hz by a pair of platinum electrodes placed in the
bath, and cell shortening was followed at one end with a video
edge-detector system. Ultraviolet light from a 100-W xenon arc lamp
(Nikon, Tokyo, Japan) was used to excite the fluorescent dye in
the cells. Light emitted at 405 and 485 nm was measured, allowing the
indo-1 ratio (405/485 signals) to be calculated. Cell shortening and
the indo-1 ratio were recorded during steady-state contractions in NT
and in the presence of 10 and 40 µM isoflavone. The change in indo-1
ratio,
indo-1 ratio (i.e., the difference between systolic and
diastolic values), was used as a measure of the
Ca2+ transient.
Effect of ICI 182,780 on Isoflavone Action.
The specific ER
antagonist ICI 182,780 (Tocris Cookson Inc., Bristol, UK) was used to
determine whether the actions of genistein and equol on cell shortening
and the Ca2+ transient were mediated via the ER.
A steady-state level of cell shortening was attained in NT during field
stimulation before 10 µM ICI 182,780 was added for 2 min. Previous
studies have demonstrated that ICI 182,780 is able to block the ER
acutely within minutes (Prakash et al., 1999
). The effects of 40 µM
isoflavone in the continuing presence of ICI 182,780 were then
determined. This was followed by a further period of superfusion in NT,
allowing parameters to return to baseline values, before the effects of 40 µM isoflavone alone were measured in the same cell.
Relation of Isoflavone Action to TK Inhibition.
The potent
and specific phosphotyrosine phosphatase (PTP) inhibitor, bpV(phen)
(Calbiochem, San Diego, CA) (Posner et al., 1994
), was used to
investigate whether any differences between genistein and equol actions
could be attributed to differences in TK inhibition. Myocytes were
superfused with 1 µM bpV(phen) for 5 min before the effects of 40 µM genistein or equol in the continuing presence of 1 µM
bpV(phen) were determined. One hundred micromolar bpV(phen) has
been reported to have no significant effect on
ICa,L in guinea pig ventricular
myocytes (Sims et al., 2000
), although we found that this concentration
of bpV(phen) markedly decreased cell shortening. We therefore chose to
use a concentration of 1 µM bpV(phen), which has been shown to be effective in inhibiting PTP in cultured hepatoma cells (Posner et al.,
1994
).
Voltage-Clamp Experiments.
Cells were impaled with
high-resistance borosilicate glass microelectrodes and
electrophysiological recordings made with an Axoclamp-2B amplifier
(Axon Instruments, Foster City, CA).
ICa,L was measured in switch-clamp
mode (discontinuous single-electrode voltage clamp, 5-6 kHz) and taken
as the difference between the peak inward current in the presence and
absence of 200 µM cadmium. Since equol tended to shift the end of
pulse current in the outward direction, in these experiments we
measured ICa,L by subtracting the
current at the end of the pulse from the peak current in the presence
and absence of the isoflavone (Ogura et al., 1999
). The effect of 40 µM genistein and equol on ICa,L were
compared with the control values in NT.
Statistical Analysis. Results are expressed as mean ± S.E.M. The repeated-measures analysis of variance with Bonferroni's post hoc test and the paired Student's t test were used to analyze the data as appropriate. A value of p < 0.05 was considered significant.
| |
Results |
|---|
|
|
|---|
Cell Shortening and Ca2+ Transients.
Genistein, 10 and 40 µM, increased baseline shortening in NT (taken as 100%) to
133 ± 7% (p < 0.05, n = 13) and
189 ± 18% (p < 0.001), respectively (Fig.
1A). In contrast, 10 and 40 µM equol
markedly decreased cell shortening to 57 ± 6% (p < 0.001, n = 9) and 40 ± 5% (p < 0.001) of control values, respectively. Daidzein had no significant
effect on cell shortening at equivalent concentrations
(n = 11). The opposing actions of genistein and equol
occurred over different timescales, as can be seen in Fig. 1B. The
stimulatory action of genistein took over a minute to reach a new
maximum steady-state level, whereas the inhibitory action of equol
occurred very rapidly within several seconds. In some cells, it was
noted that the initial washout period in NT after genistein application
produced a further increase in cell contraction before a gradual return
back to baseline levels (Fig. 1B).
|
indo-1 ratio to
114 ± 2% (p < 0.001, n = 13)
and 119 ± 4% (p < 0.001), respectively, whereas
equivalent concentrations of equol decreased the
indo-1 ratio to
87 ± 2% (p < 0.05, n = 9) and
75 ± 4% (p < 0.001) of control values.
|
Twitch Characteristics.
The time-to-peak (TTP) contraction and
time-to-half-relaxation (TTR50) were measured from the averaged trace
of eight twitches during steady-state conditions (Fig.
3). TTP decreased from 230 ± 12 ms
(in NT) to 210 ± 10 ms (p < 0.05, n = 13) and 190 ± 6 ms (p < 0.001) in the presence of 10 and 40 µM genistein, respectively. Similarly, 10 and 40 µM genistein decreased TTR50 from 110 ± 9 ms to 90 ± 7 ms (p < 0.001) and 80 ± 5 ms
(p < 0.001), respectively. Daidzein only affected
twitch kinetics at the higher concentration; TTP was decreased from
290 ± 20 ms to 250 ± 15 ms (p < 0.001, n = 10), and TTR50 decreased from 175 ± 24 ms to
150 ± 20 ms (p < 0.05) in the presence of 40 µM daidzein. Equol did not significantly alter twitch kinetics of
cell shortening (n = 9).
|
|
Effect of ICI 182,780 on Genistein and Equol Actions.
The
stimulatory effects of genistein and inhibitory effects of equol on
cell shortening and the Ca2+ transient were still
seen in the presence of 10 µM ICI 182,780 (Fig.
5). ICI 182,780 alone had no significant
effects on cell shortening or the
indo-1 ratio (n = 9 cells; data not shown). There was no statistical difference in the
extent of genistein or equol actions in the presence and absence of ICI
182,780.
|
Effect of bpV(phen) on Genistein and Equol Actions.
Genistein
(40 µM) increased cell shortening to 128 ± 11%
(p < 0.05, n = 17) in the presence of
1 µM bpV(phen) compared with cell shortening in bpV(phen) alone (Fig.
6A). However, in contrast to the previous
effects of genistein on the Ca2+ transient, there
was no associated increase in the Ca2+ transient
when genistein was applied in the presence of bpV(phen) [
indo-1
ratio after genistein application was 91 ± 4% of control values
in bpV(phen), n = 17, p = nonsignificant]. Equol (40 µM) continued to significantly
decrease cell shortening and the Ca2+ transient
in the presence of bpV(phen) (n = 14).
|
indo-1 ratio in the presence of bpV(phen). A sample
continuous recording of cell shortening and the indo-1 ratio from the
same cell is shown in Fig. 6B, in which genistein, in the presence of
bpV(phen), produced clearly divergent actions on the two parameters.
Superfusion of cells with bpV(phen) also altered the effects of
genistein on twitch kinetics. Although 40 µM genistein continued to
shorten TTP contraction in the presence of bpV(phen), TTR50 was no
longer affected (Fig. 7). Similarly,
bpV(phen) abolished the effects of genistein on the
Ca2+ transient kinetics.
|
Effect of Genistein and Equol on
ICa,L.
Sample recordings showing the
inhibition of ICa,L by genistein and
equol (40 µM) are shown in Fig. 8A.
Genistein and equol decreased peak
ICa,L by 71 ± 7%
(p < 0.001, n = 12) and 55 ± 6% (p < 0.05, n = 10), respectively (Fig.
8B). Inhibition was consistent throughout the voltage range tested and
occurred rapidly within several seconds. There was no evidence of a
stimulatory effect on ICa,L in any of
the cells studied. The isoflavones did not appear to decrease the
reversal potential of ICa,L.
|
| |
Discussion |
|---|
|
|
|---|
We have reported here the novel finding that soy-derived isoflavones exert directly opposing actions on ventricular myocytes, suggesting that they possess distinctly different mechanisms of actions. Consequently, the cardiovascular protective effects attributed to isoflavones may not be due to a group effect but rather may be exerted via specific and dominating actions of individual isoflavones. Furthermore, we have shown that the isoflavone metabolite, equol, is biologically active and exerts greater cardiac effects than those of its precursor, daidzein.
We have demonstrated here that genistein and equol both significantly
inhibit ICa,L. It therefore seems
likely that this is a common mechanism of action shared by the
isoflavones, particularly in view of their close structural
similarities (Murkies et al., 1998
; Tham et al., 1998
). The
equol-induced inhibition of ICa,L resulted in an expected decrease in the Ca2+
transient and inhibition of cell contraction. However, this was not the
case with genistein, and, in fact, the opposite effect was observed.
This implies that genistein exerts additional cellular actions distinct
from its effect on ICa,L. This is
supported by the finding that genistein inhibited
ICa,L within several seconds but took
over a minute to produce maximal levels of cell stimulation and the
observation of a temporary increase in cell contraction upon washout of
genistein in NT before a return to baseline levels. Our results suggest
that genistein produces at least two competing actions on cardiac
myocytes, an initial inhibitory component mediated via
ICa,L (which has a rapid onset and
removal) and a subsequently slower, stimulatory one. The latter action appears to dominate and mask the inhibitory component, since the overall effect in most cells was that of stimulation. However, in a
minority of cells (less than 5%), genistein completely inhibited contraction. This was probably due to the complete block of
ICa,L by genistein in these cells,
preventing the initial stimulus to excitation-contraction coupling and
therefore preventing the manifestation of any subsequent stimulatory effect.
Although genistein increased both cell shortening and the Ca2+ transient, the effect on cell shortening was disproportionately greater. Moreover, in some cells, where both parameters were simultaneously measured, genistein markedly increased cell shortening without affecting the indo-1 ratio. In addition, 10 µM genistein significantly decreased the time-to-peak contraction and time-to-half-relaxation without affecting the corresponding times for the Ca2+ transient (40 µM genistein decreased both times for cell shortening and the Ca2+ transient). These observations suggest that genistein may increase myofilament Ca2+ sensitivity in addition to increasing the Ca2+ transient.
Our findings of a lack of effect of daidzein on cell shortening
initially appear to be at odds with previous studies showing that
daidzein inhibits ICa,L (Yokoshiki et
al., 1996
; Ogura et al., 1999
). However, it is possible that daidzein
also increases myofilament Ca2+ sensitivity in a
similar way to genistein. The altered twitch characteristics produced
by 40 µM daidzein may be explained by a
Ca2+-sensitizing effect. Unfortunately, we were
unable to measure the corresponding Ca2+
transients in the presence of daidzein due to the artifactual effects
of daidzein on the fluorescent properties of indo-1.
Cardiac myocytes have been shown to express functional ERs (Grohe et
al., 1997
). It has been suggested that differences in isoflavone action
may be attributed to their differing affinities for the two ERs
(Cassidy, 1999
). However, our study demonstrates that the acute cardiac
actions of genistein and equol are unlikely to be mediated through the
ER, as the effects were still observed in the presence of the specific
ER antagonist ICI 182,780. Although ICI 182,780 was originally
developed as a pure antagonist to the classical ER, ER
(Wakeling,
1995
), there is evidence that it can also block some ER
-mediated
effects (Sun et al., 1999
; Hodges et al., 2000
). Despite this, it is
still possible that the isoflavones are acting through an as yet
undetermined membrane-associated ER
that is not completely blocked
by ICI 182,780. However, there is no evidence from the present study
that the functional differences observed between the isoflavones on
cardiac myocytes are related to differences in ER affinity.
We further investigated whether the differences in cardiac actions of genistein and equol could be explained by the unique properties of genistein as a TK inhibitor. Although genistein continued to stimulate cell contraction in the presence of the potent PTP inhibitor, bpV(phen), the increase was less pronounced compared with the increase in cell contraction observed with genistein alone (cell shortening increased to 128 ± 11 and 189 ± 18% of control values, respectively). Moreover, bpV(phen) completely abolished the genistein-induced increase in the Ca2+ transient. These findings suggest that the stimulatory actions of genistein on cell shortening occur via at least two distinct mechanisms. One mechanism appears to be independent of TK inhibition and results in increased myofilament Ca2+ sensitivity. In contrast, the second mechanism appears to be related to the TK-inhibitory action of genistein and results in an increased Ca2+ transient. These inferences are further supported by the findings that 40 µM genistein continued to accelerate the TTP shortening, consistent with a sensitizing effect, but no longer affected the TTP Ca2+ transient in the presence of bpV(phen). Furthermore, the possibility that daidzein (a structural analog of genistein but lacking TK-inhibitory activity) also increases myofilament Ca2+ sensitivity is in agreement with a TK-independent sensitizing mechanism of action of genistein.
The concentrations of isoflavones used in this study (10 and 40 µM)
were greater than those generally found in the plasma of humans who
consume soy products. The maximum plasma concentration of isoflavones
after a soy-rich meal is usually of the order of 2 µM (Figtree et
al., 2000
), although this may be higher in some Asian populations that
consume a greater amount of soy-based products (Adlercreutz et al.,
1993
). However, many factors influence the plasma concentrations and
bioavailability of isoflavones (Setchell et al., 2001
). The tissue
distribution and concentrations of isoflavones have not been well
described, although there is evidence that genistein can rapidly
accumulate in brain tissue after intraperitoneal injection (Setchell,
1998
). It is possible that certain tissues might be exposed to higher
levels of isoflavones than the mean plasma levels indicate, due to
tissue accumulation.
We have shown that genistein and equol produce opposing effects at the
level of single ventricular myocytes, although it remains to be seen
whether and how this translates into any clinically beneficial or
detrimental effects in humans. If we consider isoflavones as naturally
occurring Ca2+ channel antagonists, then the
benefits of equol become clear, since the expected effects of
suppression of myocardial contractility and arterial relaxation are
observed (Chin-Dusting et al., 2001
). In contrast, our study suggests
that the beneficial effects of genistein are not as obvious as
previously thought. Genistein also appears to be a naturally occurring
Ca2+ channel antagonist and produces arterial
relaxation (Figtree et al., 2000
) in a similar way to equol. However,
our observations of stimulatory effects of genistein on isolated
ventricular myocytes suggest that genistein may in fact increase
cardiac contraction. Theoretically, this may be a detrimental effect,
especially in patients with established cardiac disease and little
functional reserve.
The net cardiac effect of the isoflavones is unknown, although the
marked and consistent decrease in cell contraction produced by equol
suggests that this may be significant. There is wide interindividual
variation in isoflavone metabolism and excretion (Wiseman, 1999
), and
synthesis of equol is dependent on gut microflora (Rowland et al.,
2000
). As a result, about one-third of the population are classed as
"good" equol excretors (Kelly et al., 1993
), and so only this
subpopulation may potentially benefit from any advantageous cardiovascular effects of equol.
In conclusion, we have shown that soy-derived isoflavones directly affect ventricular myocytes in opposing ways, with genistein increasing and equol decreasing contraction despite both isoflavones inhibiting ICa,L. These differences appear to be independent of their differing binding affinities to the ER but may be partly related to the TK-inhibitory actions of genistein. In addition, the more potent cardiac actions of equol compared with its precursor compound, daidzein, suggest that isoflavone metabolites may be more biologically significant than previously realized. The overall cardiovascular effects and possible benefits of individual isoflavones require further investigation.
| |
Footnotes |
|---|
Accepted for publication November 11, 2002.
Received for publication August 08, 2002.
This work was funded by the British Heart Foundation.
DOI: 10.1124/jpet.102.042986
Address correspondence to: Reginald Liew, Cardiac Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK. E-mail: r.liew{at}ic.ac.uk
| |
Abbreviations |
|---|
ER, estrogen receptor; TK, tyrosine kinase; PTP, phosphotyrosine phosphatase; TTP, time-to-peak; TTR50, time-to-half-relaxation; NT, normal Tyrode's.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. D. Ullrich, A. Krust, P. Collins, and K. T. MacLeod Genomic deletion of estrogen receptors ER{alpha} and ER{beta} does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2421 - H2427. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Souzeau, S. Belanger, S. Picard, and C. F. Deschepper Dietary isoflavones during pregnancy and lactation provide cardioprotection to offspring rats in adulthood Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H715 - H721. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Atkinson, C. L. Frankenfeld, and J. W. Lampe Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health Experimental Biology and Medicine, March 1, 2005; 230(3): 155 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Basu, S. Kubota, M. R. Meselhy, M. Ciotti, B. Chowdhury, M. Hartori, and I. S. Owens Gastrointestinally Distributed UDP-glucuronosyltransferase 1A10, Which Metabolizes Estrogens and Nonsteroidal Anti-inflammatory Drugs, Depends upon Phosphorylation J. Biol. Chem., July 2, 2004; 279(27): 28320 - 28329. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Liew, M. A Stagg, J. Chan, P. Collins, and K. T MacLeod Gender determines the acute actions of genistein on intracellular calcium regulation in the guinea-pig heart Cardiovasc Res, January 1, 2004; 61(1): 66 - 76. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||